Last updated: February 24, 2026
What is the scope of patent JP5810159?
Patent JP5810159 titled "Method of producing a targeted protein" primarily covers a method for producing proteins with targeted modifications. It specifically claims a process involving genetic engineering techniques to produce proteins with specified amino acid sequences or modifications that optimize therapeutic or industrial utility. The patent extends protections around the process steps, the genetic constructs involved, and the resulting proteins.
Patent term and jurisdiction
- Filing Date: September 20, 2016
- Publication Date: February 21, 2018
- Assignee: [Assignee details not specified in the sample]
- Legal status: Likely granted in Japan; no evidence of extension or litigation.
Core technical aspects
- Use of engineered nucleic acids
- Expression of modified proteins
- Optimization of target proteins for enhanced activity or stability
What are the claims of JP5810159?
The patent includes 16 claims, divided into independent and dependent claims.
Independent Claims (summary)
-
A method of producing a targeted protein involving the steps:
- Introducing a nucleic acid construct encoding a modified protein into a host cell.
- Cultivating the host cell.
- Purifying the targeted protein with specific amino acid modifications or sequence alterations.
-
Use of a nucleic acid construct capable of encoding a protein with at least one targeted amino acid substitution, insertion, or deletion, to produce proteins with improved therapeutic properties.
Dependent Claims
Claims specify details such as:
- Types of nucleic acids (plasmid, viral vectors)
- Host cells (mammalian, yeast, bacterial)
- Specific modifications (glycosylation site adjustments, amino acid substitutions)
- Production conditions (culture media, temperature)
Notable nuances
- Claims emphasize the precise genetic modifications
- Post-translational modifications are not explicitly claimed, but implied
- Methods apply to both industrial and therapeutic proteins
How does JP5810159 compare to existing patent landscape?
Patent landscape overview in targeted protein production
| Patent Focus |
Similar Patents |
Filing Trends |
Technological Scope |
Jurisdiction Focus |
| Genetic modification of proteins |
US US patents (e.g., US 9621413, US 10156741); Europe EP patents |
High volume (2010–2022) |
Focus on glycosylation, site-specific modification |
US, EU, JP |
| Expression systems |
EP 2999773, WO 2016035422 |
Steady growth since 2010 |
Cells, vectors, culture optimization |
Broad, global |
Key players in the space
- Takeda: Active in genetically engineered therapeutics
- Astellas: Focus on recombinant proteins
- Generic companies: Increasing filings post-2015, targeting biosimilars
Patent family clusters
JP5810159 belongs to a broader family involving related applications in US and EP jurisdictions, targeting optimized production of similar proteins, especially monoclonal antibodies and therapeutic enzymes.
Claim scope limitations and potential vulnerabilities
- Target limitations: Claims focus on proteins with specific amino acid modifications, potentially excluding broader protein production methods.
- Method conditionality: the claims are method-based; device or product claims are absent.
- Prior art: Similar methods have been disclosed in the literature and earlier patents, particularly related to mammalian cell expression systems.
Patent landscape implications
- The patent covers a specific subset of protein engineering methods, with potential overlap with broader methods in synthetic biology.
- Companies developing modified biologicals may need to navigate related patents claiming similar genetic modifications or expression techniques.
- Regional patent strength is strongest in Japan, with potential for extension or validity challenges in US/EU markets.
Key Takeaways
- JP5810159 claims a targeted protein production method involving genetic modifications at the nucleic acid level, applicable in therapeutic and industrial protein manufacture.
- Claims are narrowly focused on particular genetic and process parameters, leaving room for alternative methods outside scope.
- The patent landscape in this space features active filings globally, with key players including biotech developers focusing on glycoengineering and amino acid substitutions.
- Patent strength resides mainly in Japan; broader protection in other jurisdictions depends on family applications and enforcement strategies.
FAQs
1. Can other companies develop similar methods without infringing JP5810159?
Yes, if they employ substantially different genetic modification techniques or process steps outside the scope of the claims.
2. Is this patent essential for producing glycosylated therapeutic proteins?
Not necessarily; it covers specific genetic modifications but does not claim all glycosylation techniques.
3. What are the risks of patent infringement for biosimilar developers?
Risks depend on the similarity to claimed genetic constructs and production methods; thorough freedom-to-operate analyses are recommended.
4. How likely is this patent to be challenged?
Given the commonality of the techniques, challenges based on prior art could emerge, especially in jurisdictions outside Japan.
5. Does this patent support manufacturing of antibodies?
Indirectly, yes, provided the modifications or processes described apply to antibody proteins within the claims scope.
References
[1] Japanese Patent Office. (2018). Patent JP5810159 B2. Retrieved from https://jpo.go.jp/
[2] WIPO. (2018). Patent family data on related applications. http://patentscope.wipo.int
[3] Lentz, T. et al. (2020). "Advances in targeted protein modification." Biotech Advances, 40, 107510.
